Carl Hansen, AbCellera CEO
September 15, 2021 09:00 AM EDT
Deals
Discovery
Cell/Gene Tx

Look­ing for the next mR­NA break­through, Mod­er­na taps Ab­Cellera in mys­te­ri­ous an­ti­body dis­cov­ery deal

Kyle Blankenship

Mod­er­na’s suc­cess with its Covid-19 vac­cine has bust­ed the dam open on a range of po­ten­tial mR­NA ther­a­peu­tics — and now the biotech is push­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

A service from the Financial Times